Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04180072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 31, 2025 to Dec 31, 2026v5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 48 to confirmed 51
    • Study sites: 8 to 7
    • Eligibility criteria shortened, about 34 words
    v4
  3. Primary completion date: Dec 31, 2022 to Dec 31, 2025
    • Study completion date: Dec 30, 2023 to Dec 31, 2025
    v3
  4. Phase: Phase 2 to Not applicablev2 Show 10 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Study sites: 0 to 8
    • Study completion date: Jun 30, 2022 to Dec 30, 2023
    • Start date changed from estimate of Jan 1, 2020 to Mar 12, 2020
    • Interventions: Atezolizumab plus bevacizumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug)
    • Secondary endpoints expanded, about 45 words
    • Collaborators: 6 to 8
    • Eligibility criteria expanded, about 3 words
    • Study description expanded, about 1 word
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm clinical trial. The main objective is to determine the efficacy of atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with chronic hepatitis B virus infection. All eligible patients will receive atezolizumab + bevacizumab therapy.
Trial Details
NCT Number NCT04180072
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Conditions
(from sponsor)		 Carcinoma, Hepatocellular
Related terms Carcinoma, Hepatocellular
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov